3-.beta.-d-ribofuranosylthiazolo4,5-dpyrimidine nucleosides and uses thereof
CA 2566541 C · Owner: Clark, David Louis · Inventors: Averett, Devron R.; Clark, David Louis; Xiang, Alan X.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a compound selected from (see formula I), (see formula II), (see formula III) (see formula IV), (see formula V), (see formula VI) (see formula VII), (see formula VIII), (see formula IX) (see formula X), (see formula XI), (see formula XII) (see formula XIII), (see formula XIV), (see formula XV) (see formula XVI), (see formula XVII), (see formula XVIII) (see formula XIX), (see formula XX), (see formula XXI) (see formula XXII), (see formula XXIII) pharmceutically acceptable salts thereof and pharmaceutically acceptable solvates , thereof. The compounds of the invention are useful for treating a hepatitis C virus , infection in a patient.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 7, 2004 and granted October 9, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 7, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 7, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.